Published in Hepatitis Weekly, February 19th, 2001
A long-term study conducted in Israel finds that HBV mutation and liver disease progression are unwanted side effects of taking lamivudine therapy in liver transplant recipients with hepatitis B. The new study was reported in Liver Transplantation.
"This is the first study of the efficacy of long-term lamivudine therapy for patients with HBV infection after orthotopic liver transplantation...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.